Page 187 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Research on hypoxia and ECM in cancer

C

D

Figure 6. (Continued)

DNA damage, reactive oxygen species (ROS) production, treatment upregulates DCAF13 expression, potentially
apoptosis, and immunomodulation. In human breast aggravating metastasis in chemoresistant breast cancer cells.
cancer, DCAF13, overexpressed particularly in triple-
negative breast cancer (TNBC), correlates with cancer 3.6.3. Hypoxia and clinical therapy in cancer (blue)
progression by promoting migration, invasion, and EMT, Radiotherapy and chemotherapy are traditional cancer
without affecting proliferation or apoptosis. Doxorubicin therapies for breast cancer, often causing adverse effects

Volume 9 Issue 1 (2025) 179 doi: 10.36922/ejmo.7116